|
 The shot was also 100% effective in preventing illness among trial
participants in South Africa, where a new variant called B1351 is
dominant, although the number of those participants was relatively
small at 800.
While the new overall efficacy rate of 91.3% is lower than the 95%
originally reported in November for its 44,000-person trial, a
number of variants have become more prevalent around the world since
then.
Pfizer's Chief Executive Officer Albert Bourla said the updated
results, which includes data on more than 12,000 people fully
inoculated for at least six months, positions the drugmakers to
submit for full U.S. regulatory approval.
The vaccine is currently authorized on an emergency basis by the
U.S. Food and Drug Administration.
The trial data "provide the first clinical results that a vaccine
can effectively protect against currently circulating variants, a
critical factor to reach herd immunity and end this pandemic for the
global population,” Ugur Sahin, chief executive officer at BioNTech,
said in a statement.
Experts fear new variants of COVID-19 from South Africa and Brazil
may be resistant to existing vaccines and treatment. More than 300
cases of the South African variant have been detected in more than
25 U.S. states and jurisdictions, according to federal data.
[to top of second column] |
The vaccine was 100% effective in preventing severe disease as
defined by the U.S. Centers for Disease Control and Prevention and
95.3% effective in preventing severe disease as defined by the U.S.
Food and Drug Administration.
There were also no serious safety concerns observed in trial
participants up to six months after the second dose, the companies
said.
They added that it was generally equally effective irrespective of
age, race, gender or ethnicity, and among participants with a
variety of existing medical conditions.
The trial reviewed more than 900 confirmed cases of COVID-19, most
of which were among participants who received a placebo.
The release of updated results comes on the heels of separate data
that showed the vaccine is safe and effective in 12- to 15-year
olds, paving the way for the drugmakers to seek U.S. and European
approval to use the shot in this age group within weeks.
(Reporting by Carl O'Donnell in New York; additional reporting by
Michael Erman in New York; editing by Peter Henderson and Edwina
Gibbs)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
